|
Commitments and Contingencies (Details Textual 1) (USD $)
|
1 Months Ended | 0 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended | 1 Months Ended | 1 Months Ended | 9 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 31, 2012
|
Aug. 01, 2012
Rental Agreement [Member]
|
Sep. 30, 2013
Rental Agreement [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
|
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
|
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
|
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
|
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
|
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
Product Development and Patent License Agreement [Member]
|
Feb. 28, 2002
Memorial Sloan Kettering Cancer Center [Member]
License agreement [Member]
|
Sep. 30, 2013
Memorial Sloan Kettering Cancer Center [Member]
License agreement [Member]
|
Dec. 31, 2012
Memorial Sloan Kettering Cancer Center [Member]
License agreement [Member]
|
Mar. 27, 2012
Memorial Sloan Kettering Cancer Center [Member]
Clinical Trial Agreement [Member]
|
Sep. 30, 2013
Oak Ridge National Laboratory [Member]
|
Dec. 31, 2012
Oak Ridge National Laboratory [Member]
|
Aug. 06, 2012
Aptiv Solutions [Member]
|
Sep. 30, 2013
Aptiv Solutions [Member]
|
Dec. 31, 2012
Aptiv Solutions [Member]
|
Dec. 31, 2007
Aptiv Solutions [Member]
|
Aug. 12, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Sep. 30, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Maximum [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Minimum [Member]
|
Jul. 19, 2012
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Aug. 28, 2012
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
Note
|
Sep. 26, 2012
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
|
Nov. 21, 2012
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
May 09, 2011
Jamess Capital Group LLC [Member]
Transaction management agreement [Member]
|
Mar. 31, 2013
Former CEO [Member]
Separation and Settlement Agreement [Member]
|
Feb. 28, 2013
Former CEO [Member]
Separation and Settlement Agreement [Member]
Note
|
Sep. 30, 2013
Former CEO [Member]
Separation and Settlement Agreement [Member]
|
|
| Commitments and Contingencies (Textual) | ||||||||||||||||||||||||||||||||||||
| License fee payment | $ 3,000,000 | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
| Milestones payments | 7,750,000 | 7,750,000 | 1,500,000 | 1,500,000 | 750,000 | 750,000 | 750,000 | |||||||||||||||||||||||||||||
| Net sales in milestones payment | 10,000,000 | 10,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||
| Milestone payment date | Jan. 31, 2013 | Jul. 24, 2012 | ||||||||||||||||||||||||||||||||||
| Description of royalty payment | We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. | Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. | We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. | Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. | Royalty payments of 2% of net sales will be due to FHCRC. | Royalty payments of 2% of net sales will be due to FHCRC. | ||||||||||||||||||||||||||||||
| Royalty of Net Sales Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
| First commercial sale period | 12 years 6 months | |||||||||||||||||||||||||||||||||||
| Technology access fee | 50,000 | |||||||||||||||||||||||||||||||||||
| Annual maintenance fee | 50,000 | |||||||||||||||||||||||||||||||||||
| Annual research funding | 50,000 | |||||||||||||||||||||||||||||||||||
| Purchase of radioactive material used for research and development | 233,100 | 233,100 | ||||||||||||||||||||||||||||||||||
| Project estimated cost for clinical trials of drug Ac-225-HuM195 | 2,200,000 | 1,900,000 | 1,859,333 | |||||||||||||||||||||||||||||||||
| Down payment of project estimated cost percentage | 12.50% | 12.50% | ||||||||||||||||||||||||||||||||||
| Down payment for project | 239,000 | 239,000 | ||||||||||||||||||||||||||||||||||
| Clinical trial cost for approval of food and drug administration | 23,500,000 | 13,200,000 | ||||||||||||||||||||||||||||||||||
| Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) | 150,000 | 150,000 | ||||||||||||||||||||||||||||||||||
| Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) | 250,000 | 250,000 | ||||||||||||||||||||||||||||||||||
| Royalty payment for the commercial use of drugs | 37,500 | |||||||||||||||||||||||||||||||||||
| Number of Patients | 24 | |||||||||||||||||||||||||||||||||||
| Amount paid to each patient after Completing clinical trial | 31,185 | 31,366 | 481,204 | 38,501 | 31,771 | |||||||||||||||||||||||||||||||
| Start-up fee for clinical trial | 79,623 | 19,749 | 33,946 | 22,847 | 16,000 | |||||||||||||||||||||||||||||||
| Start-up due cost paid date | Jul. 10, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | |||||||||||||||||||||||||||||||||
| Non - refundable institutional fee | 14,500 | |||||||||||||||||||||||||||||||||||
| Annual pharmacy fee | 2,025 | |||||||||||||||||||||||||||||||||||
| Amendment processing fee | 500 | |||||||||||||||||||||||||||||||||||
| Monthly fee received by management firm | 12,500 | |||||||||||||||||||||||||||||||||||
| Percentage of fully diluted capital stock equal to common stock | 10.00% | |||||||||||||||||||||||||||||||||||
| Warrant exercisable notice period description | The warrants contain a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver. | |||||||||||||||||||||||||||||||||||
| Description of period of shares availability by exercise of warrant | The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transfered until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective. | |||||||||||||||||||||||||||||||||||
| Maximum amount of out of pocket expenses | 5,000 | |||||||||||||||||||||||||||||||||||
| Consideration pursuant to agreement | The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012. | |||||||||||||||||||||||||||||||||||
| Amount payable in installments under agreement | 250,000 | |||||||||||||||||||||||||||||||||||
| Number Of Installments | 2 | |||||||||||||||||||||||||||||||||||
| Performance bonus payable under agreement for service | 60,000 | |||||||||||||||||||||||||||||||||||
| Rental agreement renewal description | The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. | |||||||||||||||||||||||||||||||||||
| Payment of first installment for services by company | 125,000 | |||||||||||||||||||||||||||||||||||
| Outstanding payment of final installment for services by company | 125,000 | |||||||||||||||||||||||||||||||||||
| Payment of performance bonus for services by company | $ 60,000 | |||||||||||||||||||||||||||||||||||
| Rent agreement termination date | Jan. 31, 2013 | Jan. 31, 2013 | ||||||||||||||||||||||||||||||||||
| Notice period for termination of agreement | 60 days prior to January 1, 2013 | The agreement terminated May 31, 2013. | ||||||||||||||||||||||||||||||||||